MediWound Ltd. Holds Special Shareholder Meeting

TL;DR

MediWound held a shareholder meeting on 12/19/24 to vote on one proposal.

AI Summary

MediWound Ltd. held a special general meeting of shareholders on December 19, 2024. The primary agenda item was a single proposal, detailed in their notice and proxy statement, which was attached to a prior Form 6-K filing as Exhibit 99.1.

Why It Matters

Shareholder meetings are crucial for corporate governance, allowing investors to vote on important company matters and influencing the direction of the company.

Risk Assessment

Risk Level: low — This filing is a routine report of a shareholder meeting and does not introduce new financial or operational risks.

Key Players & Entities

• MediWound Ltd. (company) — Filer of the report
• December 19, 2024 (date) — Date of the special general meeting of shareholders

FAQ

Filing Documents

• zk2432477.htm (6-K) — 12KB
• 0001178913-24-004013.txt ( ) — 13KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant's name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Results of Special Shareholder Meeting On December 19, 2024, MediWound Ltd. (" we ," " us " or the " Company ") held its special general meeting of shareholders (the " Meeting "). At the Meeting, our shareholders voted on one proposal, which is listed below and was described in more detail in our notice and proxy Based on the presence in person or by proxy at the Meeting of 4,049,940 (or 37.5%) of our outstanding ordinary shares, par value New Israeli Shekels (NIS) 0.07 per share (" ordinary shares ") as of the November 12, 2024 record date for the Meeting, constituting the requisite quorum, the following numbered proposal, which was presented for a vote at the Meeting, was approved by the below majority of our shareholders under the Israeli Companies Law, 5759-1999 (the " Companies Law ") (the majority, as reflected in the percentages presented below, was determined after excluding abstentions, in accordance with the Companies Law): (1) Adoption of the Company's 2024 Share Incentive Plan, under which 280,375 ordinary shares will be rolled over from the Company's expiring 2014 Equity Incentive Plan: Votes in Favor Votes Against Abstentions 3,498,317 (88%) 477,214 (12%) 74,409 Incorporation by Reference The content of this report on Form 6-K, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022 and August 15, 2023 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997, respectively) and on Form F-3 filed with the SEC on May 25, 2022 and August 29, 2024 (Registration Nos. 333-265203 and 333-281843, respectively). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: December 19, 2024 MEDIWOUND LTD. By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR